Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 1 Jan 2018

Doki Kosuke

Abstract excerpt

Antiarrhythmic drugs require therapeutic drug monitoring (TDM) to avoid adverse effects such as proarrhythmia. However, TDM is not necessarily used to adjust the dosage of antiarrhythmic drugs because there is a lack of information regarding the therapeutic range of the serum concentration and the selection of patients who require TDM. The aim of this review was to provide an overview of the pharmacogenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Anti-Arrhythmia Agents
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Flecainide

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Receptors, Adrenergic, beta-1

Share to Sodium Channel Blockers

Source

Identifiers

PMID: 30175758
DOI: 10.1248/yakushi.18-00114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].PMID 30175758Read ↗

Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.Semantic proximity Read ↗

CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.Semantic proximity Read ↗

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.Semantic proximity Read ↗

Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?Semantic proximity Read ↗

Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study.Semantic proximity Read ↗

Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.Semantic proximity Read ↗

[Pharmacogenetic aspects of antiarrhythmic drug therapy].Semantic proximity Read ↗

The genetics of pro-arrhythmic adverse drug reactions.Semantic proximity Read ↗

Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.Semantic proximity Read ↗

CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric PatientsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.